Evangelia K. Kokalaki

London, ENG W127FP, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains.

Antibody format matters: A comparative analysis of VHH and scFv domains reveals superior in vivo CAR T cell function with VHH domains.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 04, 2025

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 16, 2023

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.

CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.

Journal: Blood

Published: March 31, 2023

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2.

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2.

Journal: Frontiers in immunology

Published: December 08, 2022

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: September 03, 2022

Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors.

Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors.

Journal: Cancer immunology research

Published: August 10, 2022

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.

Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.

Journal: Nature communications

Published: March 21, 2022

Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction.

Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction.

Journal: Scientific reports

Published: August 05, 2021

Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma.

Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma.

Journal: Science translational medicine

Published: July 07, 2020

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

Journal: Blood

Published: June 28, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026